REFERENCES
- Tossavainen A. Global use of asbestos and the incidence of mesothelioma. Int. J. Occup. Environ. Health 2004; 10: 22–25
- Wagner J. C., Sleggs C. A., Marchand P. Diffuse pleural mesothelioma and asbestos exposure in the North Western Cape Province. Br. J. Ind. Med. 1960; 17: 260–271
- Kamp D. W., Israbian V. A., Preusen S. E., Zhang C. X., Weitzman S. A. Asbestos causes DNA strand breaks in cultured pulmonary epithelial cells: role of iron-catalyzed free radicals. Am. J. Physiol. 1995; 268: L471–L480
- Ault J. G., Cole R. W., Jensen C. G., Jensen L. C., Bachert L. A., Rieder C. L. Behavior of crocidolite asbestos during mitosis in living vertebrate lung epithelial cells. Cancer Res. 1995; 55: 792–798
- Hilliard A. K., Lovett J. K., McGavin C. R. The rise and fall in incidence of malignant mesothelioma from a British Naval Dockyard, 1979–1999. Occup. Med. (Lond) 2003; 53: 209–212
- Sun X., Dobra K., Bjornstedt M., Hjerpe A. Upregulation of 9 genes, including that for thioredoxin, during epithelial differentiation of mesothelioma cells. Differentiation 2000; 66: 181–188
- Kahlos K., Soini Y., Saily M., Koistinen P., Kakko S., Paakko P., Holmgren A., Kinnula V. L. Up-regulation of thioredoxin and thioredoxin reductase in human malignant pleural mesothelioma. Int. J. Cancer 2001; 95: 198–204
- Rihn B. H., Mohr S., McDowell S. A., Binet S., Loubinoux J., Galateau F., Keith G., Leikauf G. D. Differential gene expression in mesothelioma. FEBS Lett. 2000; 480: 95–100
- Mohr S., Rihn B. [Gene expression profiling in human mesothelioma cells using DNA microarray and high-density filter array technologies]. Bull. Cancer 2001; 88: 305–313
- Mohr S., Bottin M. C., Lannes B., Neuville A., Bellocq J. P., Keith G., Rihn B. H. Microdissection, mRNA amplification and microarray: a study of pleural mesothelial and malignant mesothelioma cells. Biochimie 2004; 86: 13–19
- Nymark P., Lindholm P. M., Korpela M. V., Lahti L., Ruosaari S., Kaski S., Hollmen J., Anttila S., Kinnula V. L., Knuutila S. Gene expression profiles in asbestos-exposed epithelial and mesothelial lung cell lines. BMC Genomics 2007; 8: 62
- Ceresoli G. L., Locati L. D., Ferreri A. J., Cozzarini C., Passoni P., Melloni G., Zannini P., Bolognesi A., Villa E. Therapeutic outcome according to histologic subtype in 121 patients with malignant pleural mesothelioma. Lung Cancer 2001; 34: 279–287
- Sun X., Wei L., Liden J., Hui G., Dahlman-Wright K., Hjerpe A., Dobra K. Molecular characterization of tumor heterogeneity and malignant mesothelioma cell differentiation by gene profiling. J. Pathol. 2005; 207: 91–101
- Holmgren A., Bjornstedt M. Thioredoxin and thioredoxin reductase. Methods Enzymol 1995; 252: 199–208
- Arner E. S., Holmgren A. The thioredoxin system in cancer. Sem. Cancer Biol. 2006; 16: 420–426
- Bjornstedt M., Kumar S., Bjorkhem L., Spyrou G., Holmgren A. Selenium and the thioredoxin and glutaredoxin systems. Biomed Environ. Sci. 1997; 10: 271–279
- Marzano C., Gandin V., Folda A., Scutari G., Bindoli A., Rigobello M. P. Inhibition of thioredoxin reductase by auranofin induces apoptosis in cisplatin-resistant human ovarian cancer cells. Free Radic. Biol. Med. 2007; 42: 872–881
- Rigobello M. P., Scutari G., Boscolo R., Bindoli A. Induction of mitochondrial permeability transition by auranofin, a gold(I)-phosphine derivative. Br. J. Pharmacol. 2002; 136: 1162–1168
- Powis G., Kirkpatrick D. L. Thioredoxin signaling as a target for cancer therapy. Curr. Opin. Pharmacol. 2007; 7: 392–397
- Dobra K., Andang M., Syrokou A., Karamanos N. K., Hjerpe A. Differentiation of mesothelioma cells is influenced by the expression of proteoglycans. Exp. Cell Res. 2000; 258: 12–22
- Nilsonne G., Sun X., Nystrom C., Rundlof A., Potamitou K., Fernandes A., Bjornstedt M., Dobra K. Selenite induces apoptosis in sarcomatoid malignant mesothelioma cells through oxidative stress. Free Radic. Biol. Med. 2006; 41: 874–885
- Sun X., Gulyas M., Hjerpe A., Dobra K. Proteasome inhibitor PSI induces apoptosis in human mesothelioma cells. Cancer Let. 2006; 232: 161–169
- Gordon G. J., Mani M., Maulik G., Mukhopadhyay L., Yeap B. Y., Kindler H. L., Salgia R., Sugarbaker D. J., Bueno R. Preclinical studies of the proteasome inhibitor bortezomib in malignant pleural mesothelioma. Cancer Chemother. Pharmacol 2007